![]() The management also stated that Sarissa’s intervention would disrupt the company’s future value.Īmarin has also stated that it has filed a preliminary proxy statement with the SEC with regard to the special meeting requisitioned by Sarissa and the date of this meeting will be announced shortly. Subsequently, Amarin responded to the above critiques by calling Sarissa’s statements as “inaccurate and misleading”. launch of Amarin’s sole marketed drug Vascepa’s generics. ![]() Sarissa also accused the company of lagging behind its strategic targets, including its slow response to the U.S. This dispute escalated last week when Sarissa renewed its criticisms on Amarin’s board and further accused management of causing a significant loss in shareholders’ wealth. It also defended its board refreshment process by highlighting the new strategic directions, including a cost-reduction program and other cash preservation initiatives. However, Amarin’s management has defended itself against the above statements stating that the company has actively engaged with Sarissa since the firm's equity stake became public knowledge in November 2021. This step was taken by Sarissa as it believes that the company’s board refreshment process was a “charade” and that the board has rejected attempts to add any shareholder representatives to the board. The former seeks to add seven directors to the company’s board and remove the current chairman, Per Wold-Olsen, from the board. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.The primary reason for the decline is the ongoing tussle of the company with its largest shareholder, Sarissa Capital Management LP ("Sarissa").Įarlier this month, Sarissa submitted a notice to Amarin to call a special meeting of the company’s shareholders. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. The information that Amarin posts on these channels and websites could be deemed to be material information. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.Īvailability of Other Information About AmarinĪmarin communicates with its investors and the public using the company website ( and the investor relations website (), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. ![]() From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Go to the investor relations section of the Company's website at Dial in within the United States: 87Ī replay of the call will also be available through the Company's website shortly after the call.Īmarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. The conference call with management will follow the release of the Company’s third quarter 2023 financial results in the pre-market hours. Shareholders can email any support inquiries. This Q&A platform will remain open until 24 hours before the start of the earnings call. Starting on October 19 th at 8:00 am ET, all shareholders can submit questions by visiting. To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow retail and institutional shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call. 19, 2023 (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third quarter 2023 financial results on Wednesday, November 1 st, 2023 at 8:00 a.m. DUBLIN, Ireland and BRIDGEWATER, N.J., Oct.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |